Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 20/20 | 0.59 |
| ▸ | GSPT1 | P15170 | 9/20 | 0.59 |
| ▸ | DDB1 | Q16531 | 5/20 | 0.56 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31389719 | 0.91 | CRBN (0.57) | CRBNGSPT1DDB1IKZF3CYP2C19 | |
| SCHEMBL22906959 | 0.88 | CRBN (0.56) | CRBNGSPT1DDB1IKZF3CYP2C19 | |
| SCHEMBL23729219 | 0.87 | CRBN (0.74) | CRBNGSPT1DDB1IKZF3CYP2C19 | |
| SCHEMBL30641645 | 0.87 | CRBN (0.74) | CRBNGSPT1DDB1IKZF3CYP2C19 | |
| SCHEMBL29225875 | 0.86 | CRBN (0.61) | CRBNGSPT1 | |
| SCHEMBL26088992 | 0.86 | CRBN (0.62) | CRBNGSPT1DDB1IKZF3 | |
| SCHEMBL26087642 | 0.86 | CRBN (0.62) | CRBNGSPT1DDB1IKZF3 | |
| SCHEMBL30631045 | 0.84 | CRBN (0.61) | CRBNGSPT1DDB1IKZF3CYP2C19 | |
| SCHEMBL21069987 | 0.84 | CRBN (0.66) | CRBNGSPT1DDB1IKZF3CYP2C19 | |
| SCHEMBL26740607 | 0.82 | CRBN (0.53) | CRBNGSPT1DDB1IKZF3CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240299559-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF | MONTE ROSA THERAPEUTICS AG (CH) | 2024-09-12 | — | — | US | disclosed |
| WO-2023069700-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF | MONTE ROSA THERAPEUTICS, INC. (US) | 2023-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240299559-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF | CDK2, SKP2, CDK1 | CRBN 221/4885GSPT1 851/4885DDB1 84/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.